Uppsala, Sweden, 2011-09-08 08:58 CEST (GLOBE NEWSWIRE) --
Oasmia Pharmaceutical AB (publ)
Interim report for the period May - July 2011
POSITIVE PHASE III RESULTS FOR PACLICAL®
FIRST QUARTER May 1 – July 31, 2011
- Consolidated net sales amounted to € 98 thousands (5) [1]
- Operating income amounted to € -1,690 thousands (-1,234)
- Net income after tax amounted to € -1,679 thousands (-1,330)
- Earnings per share was € -0.03 (-0.03)
- Comprehensive income amounted to € -1,679 thousands (-1,330)
- Positive results from an interim analysis of Paclical®
- Licence agreement signed for Paclical® in Israel and Turkey
EVENTS AFTER CLOSING DAY
- Oasmia and Orion terminates collaboration for Paclical® in the Nordic region
[1]The numbers in parentheses concerns results for the corresponding period previous year
Weine Nejdemo, CFO, Tel: +46 18 50 54 40 e-mail: info@oasmia.com www.oasmia.com German contacts: Dr. Sönke Knop, Peggy Kropmanns, edicto GmbH, Frankfurt, Germany. E-Mail: oasmia@edicto.de, Phone: +49 (0) 69 90 55 05 51. www.nasdaqomxnordic.com www.boerse-frankfurt.de
